CTOs on the Move

Opus Genetics

www.opusgtx.com

 
Opus Genetics is a groundbreaking gene therapy company for inherited retinal diseases with a unique model and purpose. Backed by Foundation Fighting Blindness`s venture arm, the RD Fund, Opus combines unparalleled insight and commitment to patient need with wholly owned programs in numerous orphan retinal diseases.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Masonry Technology Inc

Masonry Technology Inc is a Moreno Valley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BH1 (Better Health for Everyone)

BH1 (Better Health for Everyone) is a Franklin, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mirna Therapeutics

Mirna Therapeutics, Inc. (Mirna) is a biotechnology research and development company focused on miRNA-directed oncology therapies. Featuring world-class research capabilities, a strong understanding of miRNA and cancer biology, and a broad IP portfolio, Mirna Therapeutics is well-positioned to capitalize on the emerging field of miRNA-based therapeutics.

XOMA

XOMA is a late-stage biotechnology company with a diverse portfolio of innovative therapeutic antibodies. The Company has built an expertise in allosteric modulation and has applied that expertise to expand the therapeutic potential of monoclonal antibodies.  The first compound from XOMA’s allosteric modulating antibody program is gevokizumab, an IL-1 beta modulating antibody.  XOMA has partnered with SERVIER, a global pharmaceutical company based in France, to develop and commercialize gevokizumab for the global market, and the companies are conducting a global Phase 3 program in people with Behçet’s disease uveitis and non-infectious uveitis. Each company also has a proof-of-concept (POC) clinical program in place to identify other IL-1 mediated diseases that could be treated with gevokizumab.  One of these POC studies led XOMA to select its next Phase 3 indication, pyoderma gangrenosum, a rare ulcerative skin disease. XOMA`s scientific research also produced the XMet program, which consists of three classes of preclinical allosteric modulating antibodies, including Selective Insulin Receptor Modulators (SIRMs) that could have a major impact on the treatment of diabetes.  XOMA will retain the compound that has potential to treat several rare insulin dysfunction-related diseases and to out-license the compounds that could address the diabetes markets. 

DxTech

DxTech LLC is a Merrimack, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.